Top

Published in:

Open Access 01-08-2017

Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study

Authors: Jan K. Nowak, Irena Wojsyk-Banaszak, Edyta Mądry, Andrzej Wykrętowicz, Patrycja Krzyżanowska, Sławomira Drzymała-Czyż, Agata Nowicka, Andrzej Pogorzelski, Ewa Sapiejka, Wojciech Skorupa, Mariusz Szczepanik, Aleksandra Lisowska, Jaroslaw Walkowiak

Published in: Lung | Issue 4/2017

Abstract

Purpose

As life expectancy in cystic fibrosis (CF) increases, questions regarding its potential impact on cardiovascular health arise. Soluble vascular cell adhesion molecule 1 (sVCAM-1), P-selectin (sP-selectin) are proposed as biomarkers of cardiovascular disease. We aimed to: compare their concentrations in clinically stable CF patients and healthy subjects (HS) and verify whether they independently correlate with CF characteristics.

Methods

Serum sVCAM-1 and sP-selectin levels were measured using ELISA. CF was characterized using: forced expiratory volume in 1 s, exocrine pancreatic and CF-related liver disease status, Pseudomonas aeruginosa colonization, serum high-sensitivity C-reactive protein, and body mass index (BMI). CFTR genotypes were classified as severe (classes I and II) or other.

Results

108 CF patients and 51 healthy subjects volunteered for the study. In the CF group BMI was lower (median [IQR]: 20.5 kg/m² [18.4–22.2] vs. 21.6 kg/m² [19.9–23.4], p = 0.02) and hsCRP levels were higher (3.6 mg/L [1.1–7.1] vs. 0.5 mg/dL [0.3–1.0], p < 10⁻¹⁰). While sVCAM-1 concentrations were greater in CF patients (1018 ng/mL [851–1279] vs. 861 ng/mL [806–979], p < 10⁻⁴), sP-selectin levels did not differ (155 ng/mL [129–188] vs. 156 ng/mL [144–177], p = 0.48). None of the multivariable regression models was valid for the prediction of sVCAM-1 and sP-selectin in CF.

Conclusions

We found higher sVCAM-1 concentrations in CF patients than in healthy subjects, which were not explained by CF characteristics. Further research is required to check whether sVCAM-1 is a marker of microangiopathy in CF.

Drzymała-Czyż S, Krzyżanowska P, Koletzko B et al (2017) Determinants of serum glycerophospholipid fatty acids in cystic fibrosis. Int J Mol Sci. doi:10.3390/ijms18010185 PubMedPubMedCentral

Poore S, Berry B, Eidson D et al (2013) Evidence of vascular endothelial dysfunction in young patients with cystic fibrosis. Chest 143:939–945. doi:10.1378/chest.12-1934 CrossRefPubMed

Buehler T, Steinmann M, Singer F et al (2012) Increased arterial stiffness in children with cystic fibrosis. Eur Respir J 39:1536–1537. doi:10.1183/09031936.00212511 CrossRefPubMed

Sellers ZM, Kovacs A, Weinheimer CJ, Best PM (2013) Left ventricular and aortic dysfunction in cystic fibrosis mice. J Cyst Fibros 12:517–524. doi:10.1016/j.jcf.2012.11.012 CrossRefPubMed

Cybulsky MI, Gimbrone MA (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251:788–791CrossRefPubMed

Blankenberg S, Rupprecht HJ, Bickel C et al (2001) Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104:1336–1342CrossRefPubMed

van der Leeuw J, Beulens JWJ, van Dieren S et al (2016) novel biomarkers to improve the prediction of cardiovascular event risk in type 2 diabetes mellitus. J Am Heart Assoc 5:e003048. doi:10.1161/JAHA.115.003048 CrossRefPubMedPubMedCentral

Willeit K, Pechlaner R, Willeit P et al (2017) Association between vascular cell adhesion molecule 1 and atrial fibrillation. JAMA Cardiol 2:516–523. doi:10.1001/jamacardio.2017.0064 CrossRefPubMed

Tchalla AE, Wellenius GA, Sorond FA et al (2017) Elevated soluble vascular cell adhesion molecule-1 is associated with cerebrovascular resistance and cognitive function. J Gerontol A Biol Sci Med Sci 72:560–566. doi:10.1093/gerona/glw099 PubMed

10.

Signorelli SS, Anzaldi M, Libra M et al (2016) Plasma levels of inflammatory biomarkers in peripheral arterial disease: results of a cohort study. Angiology 67:870–874. doi:10.1177/0003319716633339 CrossRefPubMed

11.

de Faria AP, Ritter AMV, Sabbatini AR et al (2016) Deregulation of soluble adhesion molecules in resistant hypertension and its role in cardiovascular remodeling. Circ J 80:1196–1201. doi:10.1253/circj.CJ-16-0058 CrossRefPubMed

12.

Sun C-Q, Zhong C-Y, Sun W-W et al (2016) Elevated type II secretory phospholipase A2 increases the risk of early atherosclerosis in patients with newly diagnosed metabolic syndrome. Sci Rep 6:34929. doi:10.1038/srep34929 CrossRefPubMedPubMedCentral

13.

Ridker PM, Buring JE, Rifai N (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103:491–495CrossRefPubMed

14.

Chen W-S, Chen S-J, Lee C-C et al (2013) Plasma P-selectin predicts long-term cardiovascular events in hospitalized patients with suspected coronary artery disease and preserved left ventricular function: a 10-year follow-up study. Biomed J 36:137–143. doi:10.4103/2319-4170.113231 CrossRefPubMed

15.

Burgess JL, Kurzius-Spencer M, Gerkin RD et al (2012) Risk factors for subclinical atherosclerosis in firefighters. J Occup Environ Med 54:328–335. doi:10.1097/JOM.0b013e318243298c CrossRefPubMed

16.

Bielinski SJ, Berardi C, Decker PA et al (2015) P-selectin and subclinical and clinical atherosclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 240:3–9. doi:10.1016/j.atherosclerosis.2015.02.036 CrossRefPubMedPubMedCentral

17.

Berardi C, Wassel CL, Decker PA et al (2017) Elevated levels of adhesion proteins are associated with low ankle-brachial index. Angiology 68:322–329. doi:10.1177/0003319716659178 CrossRefPubMed

18.

Rodriguez-Miguelez P, Thomas J, Seigler N et al (2016) Evidence of microvascular dysfunction in patients with cystic fibrosis. Am J Physiol Heart Circ Physiol 310:H1479–H1485. doi:10.1152/ajpheart.00136.2016 CrossRefPubMedPubMedCentral

19.

De Rose V, Oliva A, Messore B et al (1998) Circulating adhesion molecules in cystic fibrosis. Am J Respir Crit Care Med 157:1234–1239. doi:10.1164/ajrccm.157.4.9704134 CrossRefPubMed

20.

Romano M, Collura M, Lapichino L et al (2001) Endothelial perturbation in cystic fibrosis. Thromb Haemost 86:1363–1367PubMed

21.

Sturm A, Hebestreit H, Koenig C et al (2010) Platelet proinflammatory activity in clinically stable patients with CF starts in early childhood. J Cyst Fibros 9:179–186. doi:10.1016/j.jcf.2009.12.004 CrossRefPubMed

22.

Madry E, Nowak J, Wykretowicz A et al (2015) Predicting the risk of atherosclerosis in patients with cystic fibrosis—rationale and design of a prospective cohort study. J Med Sci 84:126–128

23.

Foundation Cystic Fibrosis, Borowitz D, Parad RB et al (2009) Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 155:S106–S116. doi:10.1016/j.jpeds.2009.09.003 CrossRef

24.

Walkowiak J, Nousia-Arvanitakis S, Cade A et al (2002) Fecal elastase-1 cut-off levels in the assessment of exocrine pancreatic function in cystic fibrosis. J Cyst Fibros 1:260–264CrossRefPubMed

25.

Walkowiak J, Nousia-Arvanitakis S, Agguridaki C et al (2003) Longitudinal follow-up of exocrine pancreatic function in pancreatic sufficient cystic fibrosis patients using the fecal elastase-1 test. J Pediatr Gastroenterol Nutr 36:474–478CrossRefPubMed

26.

Debray D, Kelly D, Houwen R et al (2011) Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 10:S29–S36. doi:10.1016/S1569-1993(11)60006-4 CrossRefPubMed

27.

Pressler T, Bohmova C, Conway S et al (2011) Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros 10(Suppl 2):S75–S78. doi:10.1016/S1569-1993(11)60011-8 CrossRefPubMed

28.

von Elm E, Altman DG, Egger M et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4:e296. doi:10.1371/journal.pmed.0040296 CrossRef

29.

Kaplanski G, Marin V, Fabrigoule M et al (1998) Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 92:1259–1267PubMed

30.

Hulok A, Sciborski K, Marczak J et al (2014) Soluble cell adhesion molecules—does estimating sVCAM-1 and sICAM-1 concentration provide additional information about cardiovascular risk in patients with coronary artery disease? Adv Clin Exp Med 23:735–741CrossRefPubMed

31.

Vasilev V, Matrozova J, Elenkova A et al (2013) Asymmetric dimethylarginine (ADMA) and soluble vascular cell adhesion molecule 1(sVCAM-1) as circulating markers for endothelial dysfunction in patients with pheochromocytoma. Exp Clin Endocrinol Diabetes 121:551–555. doi:10.1055/s-0033-1353183 CrossRefPubMed

32.

Glowinska B, Urban M, Peczynska J, Florys B (2005) Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism 54:1020–1026. doi:10.1016/j.metabol.2005.03.004 CrossRefPubMed

33.

Veas CJ, Aguilera VC, Muñoz IJ et al (2011) Fetal endothelium dysfunction is associated with circulating maternal levels of sE-selectin, sVCAM1, and sFlt-1 during pre-eclampsia. J Matern Fetal Neonatal Med 24:1371–1377. doi:10.3109/14767058.2011.556204 CrossRefPubMed

34.

Zawiejska A, Wender-Ozegowska E, Brazert J (2010) Microvascular complications are associated with low levels of maternal sE-selectin and sVCAM-1 in pregnancy complicated with pregestational diabetes mellitus. Diabetes Res Clin Pract 88:164–170. doi:10.1016/j.diabres.2010.01.011 CrossRefPubMed

35.

Nowak M, Wielkoszyński T, Marek B et al (2008) Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. Clin Exp Med 8:159–164. doi:10.1007/s10238-008-0173-z CrossRefPubMed

36.

Nanayakkara PWB, Teerlink T, Stehouwer CDA et al (2005) Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 68:2230–2236. doi:10.1111/j.1523-1755.2005.00680.x CrossRefPubMed

37.

Miller VM, Lahr BD, Bailey KR et al (2016) Specific cell-derived microvesicles: linking endothelial function to carotid artery intima-media thickness in low cardiovascular risk menopausal women. Atherosclerosis 246:21–28. doi:10.1016/j.atherosclerosis.2015.12.030 CrossRefPubMed

38.

Postadzhiyan AS, Tzontcheva AV, Kehayov I, Finkov B (2008) Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes. Clin Biochem 41:126–133. doi:10.1016/j.clinbiochem.2007.09.001 CrossRefPubMed

39.

Lee I-T, Wang J-S, Lee W-J et al (2017) The synergistic effect of vascular cell adhesion molecule-1 and coronary artery disease on brain-derived neurotrophic factor. Clin Chim Acta 466:194–200. doi:10.1016/j.cca.2017.01.026 CrossRefPubMed

40.

Dessein PH, Joffe BI, Singh S (2005) Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 7:R634–R643. doi:10.1186/ar1717 CrossRefPubMedPubMedCentral

41.

Christoph MJ, Allison MA, Pankow JS et al (2016) Impact of adiposity on cellular adhesion: the Multi-Ethnic Study of Atherosclerosis (MESA). Obesity (Silver Spring) 24:223–230. doi:10.1002/oby.21245 CrossRef

42.

Nygaard H, Falch GS, Whist JE et al (2017) Acute effects of post-absorptive and postprandial moderate exercise on markers of inflammation in hyperglycemic individuals. Eur J Appl Physiol 117:787–794. doi:10.1007/s00421-017-3576-2 CrossRefPubMed

43.

Haliga RE, Iancu RI, Butcovan D, Mocanu V (2013) Flaxseed prevents leukocyte and platelet adhesion to endothelial cells in experimental atherosclerosis by reducing sVCAM-1 and vWF. ScientificWorldJournal 2013:303950. doi:10.1155/2013/303950 CrossRefPubMedPubMedCentral

44.

Sager HB, Dutta P, Dahlman JE et al (2016) RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med 8:342ra80. doi:10.1126/scitranslmed.aaf1435 CrossRefPubMedPubMedCentral

45.

Deng H, Song Z, Xu H et al (2017) MicroRNA-1185 promotes arterial stiffness though modulating VCAM-1 and E-selectin expression. Cell Physiol Biochem 41:2183–2193. doi:10.1159/000475576 CrossRefPubMed

46.

Luc G, Arveiler D, Evans A et al (2003) Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis 170:169–176CrossRefPubMed

47.

Kunutsor SK, Bakker SJL, Dullaart RPF (2017) Soluble vascular cell adhesion molecules may be protective of future cardiovascular disease risk: findings from the PREVEND prospective cohort study. J Atheroscler Thromb. doi:10.5551/jat.38836 PubMedCentral

48.

Attia EF, Jolley SE, Crothers K et al (2016) Soluble vascular cell adhesion molecule-1 (sVCAM-1) is elevated in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. PLoS ONE 11:e0149687. doi:10.1371/journal.pone.0149687 CrossRefPubMedPubMedCentral

49.

Thielemann A, Baszczuk A, Kopczyński Z et al (2014) The clinical usefulness of assessing the concentration of cell adhesion molecules sVCAM-1 and sICAM-1 in the serum of women with primary breast cancer. Contemp Oncol (Pozn) 18:252–259. doi:10.5114/wo.2014.43492

50.

Zhou F, Chen J, Tao G et al (2014) Increased levels of exhaled sICAM1, sVCAM1, and sE-selectin in patients with non-small cell lung cancer. Respir Med 108:1670–1676. doi:10.1016/j.rmed.2014.08.003 CrossRefPubMed

51.

Kolopp-Sarda MN, Guillemin F, Chary-Valckenaere I et al (2001) Longitudinal study of rheumatoid arthritis patients discloses sustained elevated serum levels of soluble CD106 (V-CAM). Clin Exp Rheumatol 19:165–170PubMed

52.

Klimiuk PA, Sierakowski S, Domysławska I et al (2004) Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp (Warsz) 52:36–42

53.

Pope CA, Bhatnagar A, McCracken JP et al (2016) Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation. Circ Res 119:1204–1214. doi:10.1161/CIRCRESAHA.116.309279 CrossRefPubMed

54.

George SJ (2010) Atherosclerosis: molecular and cellular mechanisms. Wiley, WeinheimCrossRef

55.

Nash MC, Wade AM, Shah V, Dillon MJ (1996) Normal levels of soluble E-selectin, soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease with age. Clin Exp Immunol 103:167–170. doi:10.1046/j.1365-2249.1996.925616.x CrossRefPubMedPubMedCentral

56.

Uğurlu N, Gerceker S, Yülek F et al (2013) The levels of the circulating cellular adhesion molecules ICAM-1, VCAM-1 and endothelin-1 and the flow-mediated vasodilatation values in patients with type 1 diabetes mellitus with early-stage diabetic retinopathy. Intern Med 52:2173–2178CrossRefPubMed

57.

Deneva-Koycheva TI, Vladimirova-Kitova LG, Angelova EA, Tsvetkova TZ (2011) Serum levels of siCAM-1, sVCAM-1, sE-selectin, sP-selectin in healthy Bulgarian people. Folia Med (Plovdiv) 53:22–28

58.

Hahne M, Lenter M, Jäger U, Vestweber D (1994) A novel soluble form of mouse VCAM-1 is generated from a glycolipid-anchored splicing variant. Eur J Immunol 24:421–428. doi:10.1002/eji.1830240223 CrossRefPubMed

59.

Garton KJ, Gough PJ, Philalay J et al (2003) Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278:37459–37464. doi:10.1074/jbc.M305877200 CrossRefPubMed

60.

Singh RJR, Mason JC, Lidington EA et al (2005) Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res 67:39–49. doi:10.1016/j.cardiores.2005.02.020 CrossRefPubMed

61.

Woollard KJ, Suhartoyo A, Harris EE et al (2008) Pathophysiological levels of soluble P-selectin mediate adhesion of leukocytes to the endothelium through Mac-1 activation. Circ Res 103:1128–1138. doi:10.1161/CIRCRESAHA.108.180273 CrossRefPubMed

62.

Roller J, Wang Y, Rahman M et al (2013) Direct in vivo observations of P-selectin glycoprotein ligand-1-mediated leukocyte-endothelial cell interactions in the pulmonary microvasculature in abdominal sepsis in mice. Inflamm Res 62:275–282. doi:10.1007/s00011-012-0575-y CrossRefPubMed

63.

Angiari S, Donnarumma T, Rossi B et al (2014) TIM-1 glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during inflammation and autoimmunity. Immunity 40:542–553. doi:10.1016/j.immuni.2014.03.004 CrossRefPubMedPubMedCentral

64.

Reiner AP, Carlson CS, Thyagarajan B et al (2008) Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol 28:1549–1555. doi:10.1161/ATVBAHA.108.169532 CrossRefPubMed

65.

Ay C, Jungbauer LV, Kaider A et al (2008) P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. Thromb Haemost 99:899–904. doi:10.1160/TH07-11-0672 PubMed

66.

Woollard KJ, Lumsden NG, Andrews KL et al (2014) Raised soluble P-selectin moderately accelerates atherosclerotic plaque progression. PLoS ONE 9:e97422. doi:10.1371/journal.pone.0097422 CrossRefPubMedPubMedCentral

67.

Penman A, Hoadley S, Wilson JG et al (2015) P-selectin plasma levels and genetic variant associated with diabetic retinopathy in African Americans. Am J Ophthalmol 159(1152–1160):e2. doi:10.1016/j.ajo.2015.03.008

68.

Scialla JJ, Plantinga LC, Kao WHL et al (2011) Soluble P-selectin levels are associated with cardiovascular mortality and sudden cardiac death in male dialysis patients. Am J Nephrol 33:224–230. doi:10.1159/000324517 CrossRefPubMedPubMedCentral

69.

Lee DS, Larson MG, Lunetta KL et al (2008) Clinical and genetic correlates of soluble P-selectin in the community. J Thromb Haemost 6:20–31. doi:10.1111/j.1538-7836.2007.02805.x CrossRefPubMed

70.

Bryan LJ, Callas PW, Criqui MH, Cushman M (2012) Higher soluble P-selectin is associated with chronic venous insufficiency: the San Diego Population Study. Thromb Res 130:716–719. doi:10.1016/j.thromres.2012.07.012 CrossRefPubMedPubMedCentral

71.

Cangemi R, Pignatelli P, Carnevale R et al (2016) Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. J Infect 73:107–114. doi:10.1016/j.jinf.2016.05.013 CrossRefPubMed

72.

Cangemi R, Casciaro M, Rossi E et al (2014) Platelet activation is associated with myocardial infarction in patients with Pneumonia. J Am Coll Cardiol 64:1917–1925. doi:10.1016/j.jacc.2014.07.985 CrossRefPubMed

73.

Preston RA, Coffey JO, Materson BJ et al (2007) Elevated platelet P-selectin expression and platelet activation in high risk patients with uncontrolled severe hypertension. Atherosclerosis 192:148–154. doi:10.1016/j.atherosclerosis.2006.04.028 CrossRefPubMed

74.

Petramala L, Iacobellis G, Carnevale R et al (2016) Enhanced soluble serum CD40L and serum p-selectin levels in primary aldosteronism. Horm Metab Res 48:440–445. doi:10.1055/s-0042-103588 CrossRefPubMed

75.

Jerzykowska S, Cymerys M, Roszak M et al (2014) The analysis of the influence of short term physical effort on selected endothelial function parameters and blood vessels stiffness features among young and healthy men. Pol Merkur Lek 36:373–378

76.

Schnabel RB, Yin X, Larson MG et al (2013) Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol 33:1728–1733CrossRefPubMedPubMedCentral

77.

Patel MS, Miranda-Nieves D, Chen J et al (2017) Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome. Transl Res 183:1–13. doi:10.1016/j.trsl.2016.11.007 CrossRefPubMed

78.

Stähli BE, Gebhard C, Duchatelle V et al (2016) Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: insights from the SELECT-ACS trial. J Am Heart Assoc. doi:10.1161/JAHA.116.004255 PubMedPubMedCentral

79.

Wagner H, Lood C, Borna C et al (2016) Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients. J Thromb Thrombolysis 42:369–375. doi:10.1007/s11239-016-1372-1 CrossRefPubMed

80.

Dinkla S, van Cranenbroek B, van der Heijden WA et al (2016) Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin. Blood 127:1976–1986. doi:10.1182/blood-2015-04-640300 CrossRefPubMed

81.

Valdes V, Nardi MA, Elbaum L, Berger JS (2015) Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand. J Thromb Thrombolysis 40:83–87. doi:10.1007/s11239-015-1179-5 CrossRefPubMedPubMedCentral

82.

Cleanthis M, Smout J, Bhattacharya V et al (2008) Soluble but not platelet P-selectin correlates with spontaneous platelet aggregation: a pilot study. Clin Appl Thromb 14:227–233. doi:10.1177/1076029607305915 CrossRef

83.

Zarbock A, Singbartl K, Ley K (2006) Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116:3211–3219. doi:10.1172/JCI29499 CrossRefPubMedPubMedCentral

84.

O’Sullivan BP (2005) Platelet activation in cystic fibrosis. Blood 105:4635–4641. doi:10.1182/blood-2004-06-2098 CrossRefPubMed

85.

Samuels CE, Robinson PG, Elliott RB (1975) Decreased inhibition of platelet aggregation by PGE1 in children with cystic fibrosis and their parents. Prostaglandins 10:617–621CrossRefPubMed

Title: Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study
Authors: Jan K. Nowak
Irena Wojsyk-Banaszak
Edyta Mądry
Andrzej Wykrętowicz
Patrycja Krzyżanowska
Sławomira Drzymała-Czyż
Agata Nowicka
Andrzej Pogorzelski
Ewa Sapiejka
Wojciech Skorupa
Mariusz Szczepanik
Aleksandra Lisowska
Jaroslaw Walkowiak
Publication date: 01-08-2017
Publisher: Springer US
Published in: Lung / Issue 4/2017
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-017-0029-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Treatment with Geranylgeranylacetone Induces Heat Shock Protein 70 and Attenuates Neonatal Hyperoxic Lung Injury in a Model of Bronchopulmonary Dysplasia

Total IgM and Anti-Phosphatidylcholine IgM Antibody Secretion Continue After Clearance of Mycobacterium bovis Bacillus Calmette-Guerin Pleural Infection

Sarcoidosis in Israel: Clinical Outcome Status, Organ Involvement, and Long-Term Follow-Up

Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations

Hypertonic Saline as a Useful Tool for Sputum Induction and Pathogen Detection in Cystic Fibrosis

Dengue Hemorrhagic Fever: A State-of-the-Art Review Focused in Pulmonary Involvement

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page